Rewiring drug-activated p53-regulatory network from suppressing to promoting tumorigenesis

Journal of Molecular Cell Biology

Volumn 4, Issue 4, 2012, Pages 197-206

  Song, Wei ^a   Wang, Jiguang ^a,b   Yang, Ying ^a   Jing, Naihe ^a   Zhang, Xiangsun ^b   Chen, Luonan ^a,c   Wu, Jiarui ^a,c,d  

^a INSTITUTE OF BIOCHEMISTRY AND CELL BIOLOGY   (China)

^b CHINESE ACADEMY OF SCIENCES   (China)

^c INSTITUTE OF GEOLOGY AND GEOPHYSICS   (China)

^d UNIVERSITY OF SCIENCE AND TECHNOLOGY OF CHINA   (China)

Author keywords

5 aza 2 deoxycytidine; network; P19 EC cells; p53; tumorigenesis

Indexed keywords

5 AZA 2' DEOXYCYTIDINE; CISPLATIN; SMALL INTERFERING RNA;

ANIMAL CELL; APOPTOSIS; ARTICLE; CANCER INHIBITION; CARCINOGENESIS; CARCINOMA CELL; CELL ADHESION; CELL GROWTH; CONTROLLED STUDY; GENE EXPRESSION; GENE FUNCTION; GENE REGULATORY NETWORK; MOUSE; NONHUMAN; ONCOGENE; PROTEIN PROTEIN INTERACTION; TUMOR PROMOTION; TUMOR SUPPRESSOR GENE;

ANIMALS; AZACITIDINE; CELL ADHESION; CELL PROLIFERATION; CELL TRANSFORMATION, NEOPLASTIC; CISPLATIN; GENE EXPRESSION REGULATION, NEOPLASTIC; GENE KNOCKDOWN TECHNIQUES; GENE REGULATORY NETWORKS; MICE; PROTEIN INTERACTION MAPS; TUMOR CELLS, CULTURED; TUMOR SUPPRESSOR PROTEIN P53; UP-REGULATION;

EID: 84864856603     PISSN: 16742788     EISSN: 17594685     Source Type: Journal    
DOI: 10.1093/jmcb/mjs029     Document Type: Article

References (52)

1. Banerjee, S., and Bacanamwo, M. (2010). DNA methyltransferase inhibition induces mouse embryonic stem cell differentiation into endothelial cells. Exp. Cell Res. 316, 172-180.
2. Barabási, A., and Oltvai, Z.N. (2004). Network biology: understanding the cell's functional organization. Nat. Rev. Genet. 5, 101-113. (Pubitemid 38160277)
3. Bar-Joseph, Z., Gifford, D.K., and Jaakkola, T.S. (2001). Fast optimal leaforder-ingfor hierarchical clustering. Bioinformatics 17(Suppl 1), S22-S29. (Pubitemid 33793490)
4. Beyrouthy, M.J., Garner, K.M., Hever, M.P., et al. (2009). High DNA methyltrans-ferase 3B expression mediates 5-aza-deoxycytidine hypersensitivity in tes-ticular germ cell tumors. Cancer Res. 69, 9360-9366.
5. Blelloch, R.H., Hochedlinger, K., Yamada, Y., et al. (2004). Nuclear cloning of embryonal carcinoma cells. Proc. Natl Acad. Sci. USA 101, 13985-13990. (Pubitemid 39305016)
6. Chiarugi, P., and Giannoni, E. (2008). Anoikis: a necessary death program for anchorage-dependent cells. Biochem. Pharmacol. 76, 1352-1364.
7. Choi, S.C., Yoon, J., Shim, W.J., et al. (2004). 5-azacytidine induces cardiac dif-ferentiation of P19 embryonic stem cells. Exp. Mol. Med. 36, 515-523. (Pubitemid 40129173)
8. Curtin, J.C., Dragnev, K.H., Sekula, D., et al. (2001). Retinoic acid activates p53 in human embryonal carcinoma through retinoid receptor-dependent stimu-lation of p53 transactivation function. Oncogene 20, 2559-2569. (Pubitemid 32531353)
9. Feldser, D.M., Kostova, K.K., Winslow, M.M., et al. (2010). Stage-specificsensitiv-ity to p53 restoration during lung cancer progression. Nature 468, 572-575.
10. Fidler, I.J. (2003). The pathogenesis ofcancer metastasis: the 'seed and soil' hypothesis revisited. Nat. Rev. Cancer3, 1-6.
11. Frisch, S.M., and Francis, H. (1994). Disruption ofepithelial cell-matrix interac-tions induces apoptosis. J. Cell Biol. 124, 619-626. (Pubitemid 24064472)
12. Gidekel, S., Pizov, G., Bergman, Y., et al. (2003). Oct-3/4 is a dose-dependent oncogenic fate determinant. Cancer Cell 4, 361-370. (Pubitemid 37491097)
13. Harris, S.L., and Levine, A.J. (2005). The p53 pathway: positive and negative feedback loops. Oncogene 24, 2899-2908. (Pubitemid 40638098)
14. Hartwell, L.H., Hopfield, J.J., Leibler, S., et al. (1999). From molecular to modular cell biology. Nature 402, C47-C52.
15. Huang, D.W., Sherman, B.T., and Lempicki, R.A. (2009). Systematic and inte-grative analysis of large gene lists using DAVID Bioinformatics Resources. Nat. Protoc. 4, 44-57.
16. Jänicke, R.U., Sohn, D., and Schulze-Osthoff, K. (2008). The dark side of a tumor suppressor: anti-apoptotic p53. Cell Death Differ. 15, 959-976. (Pubitemid 351712601)
17. Junttila, M.R., Karnezis, A.N., Garcia, D., et al. (2010). Selective activation of p53-mediated tumoursuppression in high-grade tumours. Nature 468, 567-571.
18. Kaneshiro, K., Tsutsumi, S., Tsuji, S., et al. (2007). An integrated map of p53-binding sites and histone modification in the human ENCODE regions. Genomics 89, 178-188. (Pubitemid 46048964)
19. Kerley-Hamilton, J.S., Pike, A.M., Li, N., et al. (2005). A p53-dominant transcrip-tional response to cisplatin in testicular germ cell tumor-derived human embyronal carcinoma. Oncogne 24, 6090-6100. (Pubitemid 43080059)
20. Kitano, H. (2002). Systems biology: a briefoverview. Science295, 1662-1664.
21. Knoepfler, P.S. (2009). Deconstructing stem cell tumorigenicity: a roadmap to safe regenerative medicine. Stem Cells 27, 1050-1056.
22. Knowlton, N., Dozmorov, I.M., and Centola, M. (2004). Microarray Data Analysis Toolbox (MDAT): for normalization, adjustment and analysis of gene expression data. Bioinformatics 20, 3687-3690. (Pubitemid 40136817)
23. Kruse, J., and Gu, W. (2009). Mode of p53 regulation. Cell 137, 609-622.
24. Kubbutat, M.H., Jones, S.N., and Vousden, K.H. (1997). Regulation of p53 sta-bility by Mdm2. Nature 387, 299-303.
25. Lafage-Pochitaloff, M., Alcalay, M., Brunel, V., et al. (1995). Acute promyelocy-tic leukemia cases with nonreciprocal PML/RARa or RARa/PML fusion genes. Blood 85, 1169-1174.
26. Lagger, S., Meunier, D., Mikula, M., et al. (2010). Crucialfunction ofhistone dea-cetylase 1 for differentiation of teratomas in mice and humans. EMBO J. 29, 3992-4007.
27. Le Beau, M.M., Bitts, S., Davis, E.M., et al. (2002). Recurring chromosomal ab-normalities in leukemia in PML-RARA transgenic mice parallel human acute promyelocytic leukemia. Blood 99, 2985-2991. (Pubitemid 34525389)
28. Levine, A.J., and Oren, M. (2009). The first 30 years of p53: growing ever more complex. Nat. Rev. Cancer 9, 749-758.
29. Linn, D.E., Yang, X., Sun, F., et al. (2010). A role for OCT4 in tumor initiation of drug-resistant prostate cancer cells. Genes Cancer 1, 908-916.
30. Liu, B., Ordonez-Ercan, D., Fan, Z., et al. (2007). Downregulation of ErbB3 abro-gates ErbB2-mediated tamoxifen resistance in breast cancer cells. Int. J. Cancer 120, 1874-1882. (Pubitemid 46418362)
31. Lorente-Trigos, A., Varnat, F., Melotti, A., et al. (2010). BMP signaling promotes the growth of primary human colon carcinomas in vivo. J. Mol. Cell Biol. 2, 318-332.
32. Lutzker, S.G., and Levine, A.J. (1996). A functionally inactive p53 protein in teratocarcinoma cells is activated by either DNA damage or cellular differen-tiation. Nat. Med. 2, 804-810. (Pubitemid 26225098)
33. Martin, G.R. (1975). Teratocarcinomas as a model system for the study of em-bryogenesis and neoplasia. Cell 5, 229-243.
34. McMurray, H.R., Sampson, E.R., Compitello, G., et al. (2008). Synergistic re-sponse to oncogenic mutations defines gene class critical to cancer pheno-type. Nature 453, 1112-1116. (Pubitemid 351871734)
35. Menendez, D., Inga, A., and Resnick, M.A. (2009). The expanding universe of p53 targets. Nat. Rev. Cancer9, 724-737.
36. Menendez, D., Krysiak, O., Inga, A., et al. (2006). ASNP in the flt-1 promoter integrates the VEGF system into the p53 transcriptional network. Proc. Natl Acad. Sci. USA 103, 1406-1411. (Pubitemid 43191178)
37. Peng, H.Q., Hogg, D., Malkin, D., et al. (1993). Mutations of the p53 gene do not occur in testis cancer. Cancer Res. 53, 3574-3578. (Pubitemid 23229639)
38. Perissi, V., and Rosenfeld, M.G. (2005). Controlling nuclear receptors: the cir-cular logic of cofactor cycles. Nat. Rev. Mol. Cell Biol. 6, 542-554. (Pubitemid 40943045)
39. Quigley, D., and Balmain, A. (2009). Systems genetics analysis of cancer susceptibility: from mouse models to humans. Nat. Rev. Genet. 10, 651-657.
40. Shieh, S.Y., Ikeda, M., Taya, Y., et al. (1997). DNA damage-induced phosphor-ylation of p53 alleviates inhibition by MDM2. Cell91, 325-334. (Pubitemid 27467963)
41. Simpson, C.D., Anyiwe, K., and Schimmer, A.D. (2008). Anoikis resistance and tumor metastasis. Cancer Lett. 272, 177-185.
42. Sperger, J.M., Chen, X., Draper, J.S., et al. (2003). Gene expression patterns in human embryonic stem cells and human pluripotent germ cell tumors. Proc. Natl Acad. Sci. USA 100, 13350-13355. (Pubitemid 37444745)
43. Tan, K., Tegner, J., and Ravasi, T. (2008). Integrated approaches to uncovering transcription regulatory networks in mammalian cells. Genomics 91, 219-231.
44. Tweddle, D.A., Pearson, A.D., Haber, M., et al. (2003). The p53 pathway and its inactivation in neuroblastoma. Cancer Lett. 197, 93-98. (Pubitemid 36859996)
45. Vogelstein, B., Lane, D., and Levine, A.J. (2000). Surfing the p53 network. Nature 408, 307-310.
46. Wang, J., Huang, Q., Liu, Z.P., et al. (2011). NOA: a novel networkontologyana-lysis method. Nucleic Acids Res. 39, e87.
47. Woods, N.T., Yamaguchi, H., Lee, F.Y., et al. (2007). Anoikis, initiated by Mcl-1 degradation and Bim induction, is deregulated during oncogenesis. Cancer Res. 67, 10744-10752. (Pubitemid 350145901)
48. Xia, C., Wang, C., Zhang, K., et al. (2007). Induction of a high population of neural stem cells with anterior neuroectoderm characters from epiblast-like P19 embryonic carcinoma cells. Differentiation 75, 912-927. (Pubitemid 350212639)
49. Xue, L., Yuan, Q., Yang, Y., et al. (2009). Enzymatic preparation of an artificial microRNA library. Biochem. Biophys. Res. Commun. 390, 791-796.
50. Zamble, D.B., Jacks, T., and Lippard, S.J. (1998). p53-dependent and-independent responses to cisplatin in mouse testicular teratocarcinoma cells. Proc. Natl Acad. Sci. USA95, 6163-6168. (Pubitemid 28248982)
51. Zhang, X.P., Liu, F., Cheng, Z., et al. (2009). Cell fate decision mediated by p53 pulses. Proc. Natl Acad. Sci. USA 106, 12245-12250.
52. Zhang, X.P., Liu, F., and Wang, W. (2011). Two-phase dynamics of p53 in the DNA damage response. Proc. Natl Acad. Sci. USA 108, 8990-8995.